Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment

International Journal of Dermatology

Volumn 56, Issue 1, 2017, Pages 106-108

  Tiryakioğlu, Necip Ozan ^a   Önal, Zerrin ^b   Saygili, Seha K ^c   Önal, Hasan ^d   Ersoy Tunali, Nagehan ^a  

^a HALIC UNIVERSITY   (Turkey)

^b Bakirkoy Sadi Konuk Training and Research Hospital   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d Kanuni Sultan Suleyman Training and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIURETIC AGENT; DNA; KALLIKREIN INHIBITOR; POTASSIUM; BICARBONATE; DERMATOLOGICAL AGENT; DRUG COMBINATION; KALLIKREIN; LEUKOCYTE ELASTASE INHIBITOR; OINTMENT; SPINK5 PROTEIN, HUMAN; ZINC OXIDE;

ALKALOSIS; ANEMIA; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERNATREMIA; HYPERTENSION; ICHTHYOSIS; METABOLIC ALKALOSIS; MUTATIONAL ANALYSIS; NETHERTON DISEASE; NEWBORN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN EXFOLIATION; SPINK5 GENE; THROMBOCYTOPENIA; TREATMENT FAILURE; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG COMBINATION; GENE DELETION; GENETICS; NETHERTON SYNDROME; NUCLEOTIDE SEQUENCE; OINTMENT; THERAPEUTIC USE;

BASE SEQUENCE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; HUMANS; HYPERNATREMIA; ICHTHYOSIS; INFANT, NEWBORN; KALLIKREINS; NETHERTON SYNDROME; OINTMENTS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SEQUENCE DELETION; SODIUM BICARBONATE; ZINC OXIDE;

EID: 84975782902     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.13248     Document Type: Article

References (10)

1. Mägert HJ, Ständker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999; 274: 21499–21502.
2. Chavanas S, Bodemer C, Rochat A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141–142.
3. Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007; 18: 3607–3619.
4. Stevanovic DV. Multiple defects of the hair shaft in Netherton's disease. Association with ichthyosis linearis circumflexa. Br J Dermatol 1969; 81: 851–857.
5. Smith JG, Wong SW, deShazo RD. Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol 1995; 95: 116–123.
6. Stoll C, Alembik Y, Tchomakov D, et al. Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet Counsel 2001; 12: 237–243.
7. Boskabadi H, Maamouri G, Mafinejad S. Netherton syndrome, a case report and review of literature. Iran J Pediatr 2013; 23: 611–612.
8. Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat Diagn 2002; 22: 121–126.
9. Eissa A, Amodeo V, Smith CR, et al. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 2011; 286: 687–706.
10. Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 2002; 118: 436–443.